Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE 2
NCT07533175Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Primary completion
- Aug 2028
- Modality
- Peptides, Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of amycretin in type 2 diabetes mellitus (T2DM), obesity, sponsored by Novo Nordisk. Started Apr 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07533175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07533175.